Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T12:50:45.631Z.
Calculation as of: 2026-10-06T12:50:45.631Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$573.38M
PB Ratio
N/A
TTM Avg
10.63
3Y Avg
10.63
5Y Avg
10.63
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $579.88M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | N/A | 10.63 | 10.63 | 10.63 |
| CorMedix Inc. (CRMD)vs › | $569.56M | 1.24 | 2.02 | 4.79 | 4.03 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | 4.79 | 4.21 | 2.08 | 2.88 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | 1.86 | 4.83 | 5.15 | 4.11 |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | 2.41 | 13.66 | 7.56 | 5.62 |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 4.52 | 3.92 | 15.48 | 13.15 |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | 2.64 | 3.16 | 1.89 | 1.89 |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | 0.64 | 0.59 | 0.57 | 0.87 |
| Altimmune, Inc. (ALT)vs › | $519.25M | 1.09 | 1.67 | 2.47 | 2.29 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
